Helsinn Drug Patent Portfolio
Helsinn owns 1 orange book drug protected by 6 US patents Given below is the list of Helsinn's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7872050 | Stabilized compositions of volatile alkylating agents and methods of using thereof | 08 Jul, 2029 | Active |
| US7838564 | Stabilized compositions of volatile alkylating agents and methods of using thereof | 07 Mar, 2026 | Active |
| US8450375 | Stabilized compositions of volatile alkylating agents and methods of using thereof | 07 Mar, 2026 | Active |
| US8501818 | Stabilized compositions of alkylating agents and methods of using same | 07 Mar, 2026 | Active |
| US8501819 | Stabilized compositions of volatile alkylating agents and methods of using thereof | 07 Mar, 2026 | Active |
| US9382191 | Stabilized compositions of volatile alkylating agents and methods of using thereof | 07 Mar, 2026 | Active |
Latest Legal Activities on Helsinn's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Helsinn.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Jun, 2022 | US7872050 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Apr, 2022 | US7838564 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Jan, 2021 | US8501818 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Jan, 2021 | US8501819 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Oct, 2020 | US8450375 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2018 | US7872050 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 May, 2018 | US7838564 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 01 Feb, 2017 | US7872050 |
|
Email Notification
Critical
| 01 Feb, 2017 | US7872050 |
|
Correspondence Address Change
Critical
| 30 Jan, 2017 | US7872050 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Jan, 2017 | US7838564 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Jan, 2017 | US8450375 |
|
Email Notification
Critical
| 25 Jan, 2017 | US7838564 |
|
Email Notification
Critical
| 25 Jan, 2017 | US8501818 |
|
Email Notification
Critical
| 25 Jan, 2017 | US8450375 |
Helsinn's Family Patents
Helsinn drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 32.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Helsinn Drug List
Given below is the complete list of Helsinn's drugs and the patents protecting them.
1. Valchlor
Valchlor is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7872050 | Stabilized compositions of volatile alkylating agents and methods of using thereof |
08 Jul, 2029
(4 years from now)
| Active |
| US7838564 | Stabilized compositions of volatile alkylating agents and methods of using thereof |
07 Mar, 2026
(9 months from now)
| Active |
| US8450375 | Stabilized compositions of volatile alkylating agents and methods of using thereof |
07 Mar, 2026
(9 months from now)
| Active |
| US8501818 | Stabilized compositions of alkylating agents and methods of using same |
07 Mar, 2026
(9 months from now)
| Active |
| US8501819 | Stabilized compositions of volatile alkylating agents and methods of using thereof |
07 Mar, 2026
(9 months from now)
| Active |
| US9382191 | Stabilized compositions of volatile alkylating agents and methods of using thereof |
07 Mar, 2026
(9 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valchlor's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List